IceCure Medical (ICCM) grants 131K RSUs to North America VP

Rhea-AI Filing Summary

Good Shad reported acquisition or exercise transactions in this Form 4 filing.

IceCure Medical Ltd. reported that VP, Sales for North America Good Shad received a grant of 131,483 restricted share units (RSUs) on August 14, 2026. These RSUs vest 25% on August 11, 2027, with the remaining 75% vesting in twelve equal quarterly installments of 6.25% thereafter. Following this award, Shad holds a total of 136,698 ordinary share-based interests, comprising the new RSUs, 219 ordinary shares, and several prior RSU grants with similar 25%-then-quarterly vesting schedules, most of which remain unvested as of August 13, 2026. The figures reflect IceCure’s 1-for-30 reverse share split.

Insider Trade Summary

Net Buyer: 131,483 shares

Net Buy 1 txn

Insider Good Shad

Role VP, Sales for North America

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1	131,483	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 136,698 shares (Direct)

Footnotes (1)

1. F1. Represents (i) 131,483 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 219 ordinary shares, (iii) 2,021 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iv) 1,757 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (v) 1,218 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings in clauses (ii) through (v) have been adjusted to reflect the Issuer's 1-for-30 reverse share split.

Key Figures

New RSU grant: 131,483 RSUs Total holdings after grant: 136,698 shares/RSUs Grant price per share: $0.0000 per share +5 more

8 metrics

New RSU grant 131,483 RSUs Restricted share units granted to Good Shad on August 14, 2026

Total holdings after grant 136,698 shares/RSUs Ordinary shares and RSUs beneficially owned following the transaction

Grant price per share $0.0000 per share Reported transaction price per share for the RSU award

Ordinary shares held 219 shares Ordinary shares included within total post-transaction holdings

Prior RSUs July 2, 2024 2,021 RSUs RSUs granted July 2, 2024, 25% vested July 29, 2026

Prior RSUs November 5, 2025 1,757 RSUs RSUs granted November 5, 2025 with 25% vesting November 5, 2026

Prior RSUs March 16, 2026 1,218 RSUs RSUs granted March 16, 2026 with 25% vesting March 16, 2027

Reverse share split ratio 1-for-30 Issuer’s reverse share split applied to reported holdings

Key Terms

restricted share units, vesting, quarterly installments, reverse share split

4 terms

restricted share units financial

"Represents (i) 131,483 restricted share units ("RSUs") granted on August 14, 2026"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

vesting financial

"25% of which vest on August 11, 2027, and the remaining 75% vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

quarterly installments financial

"the remaining 75% vest in twelve equal quarterly installments of 6.25%"

reverse share split financial

"holdings in clauses (ii) through (v) have been adjusted to reflect the Issuer's 1-for-30 reverse share split"

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

FAQ

What equity award did IceCure Medical (ICCM) grant to Good Shad on August 14, 2026?

IceCure Medical granted 131,483 restricted share units (RSUs) to VP, Sales for North America Good Shad on August 14, 2026. The RSUs vest 25% on August 11, 2027, with the remaining 75% vesting in twelve equal quarterly installments of 6.25%.

How many IceCure Medical (ICCM) shares and RSUs does Good Shad hold after this Form 4 transaction?

After the reported grant, Good Shad holds 136,698 ordinary share-based interests. This total includes 131,483 new RSUs, 219 ordinary shares, and earlier RSU grants of 2,021, 1,757, and 1,218 units, adjusted for the reverse split.

What is the vesting schedule for the new 131,483 RSUs reported by IceCure Medical (ICCM)?

The 131,483 RSUs vest 25% on August 11, 2027. The remaining 75% then vest in twelve equal quarterly installments of 6.25% each, creating a multi-year, performance-retention oriented vesting profile for the executive.

How are Good Shad’s earlier RSU grants from 2024–2026 at IceCure Medical (ICCM) structured?

Earlier RSU grants of 2,021, 1,757, and 1,218 units each vest 25% on specified initial vesting dates, with the remaining 75% vesting in equal quarterly installments of 6.25%. Only the 25% tranche of the July 2, 2024 grant had vested by August 13, 2026.

Did the IceCure Medical (ICCM) Form 4 for Good Shad involve any share sales?

No sales were reported; the filing shows a grant/award acquisition of 131,483 RSUs coded as transaction type “A.” The transaction price per share is listed as $0.0000, consistent with a compensatory equity award rather than a market purchase.

How did IceCure Medical’s reverse share split affect Good Shad’s reported holdings?

Good Shad’s holdings in earlier items, including 219 ordinary shares and prior RSU grants, have been adjusted to reflect IceCure Medical’s 1-for-30 reverse share split. The reported totals therefore represent post-split quantities, enhancing comparability for investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 08:26 AM Accepted by SEC EDGAR 08/17/2026 - 08:26 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Good Shad

(Last) (First) (Middle)

7 HA'ESHEL ST., PO BOX 3163

(Street)

CAESAREA 3079504

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Sales for North America

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/14/2026		A		131,483	A	$0	136,698(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents (i) 131,483 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 219 ordinary shares, (iii) 2,021 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iv) 1,757 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (v) 1,218 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings in clauses (ii) through (v) have been adjusted to reflect the Issuer's 1-for-30 reverse share split.

	/s/ Shad Good	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)